Safety and Tolerability Study of 2 Dose Level of Arikayce™ in Patients With Bronchiectasis and Chronic Infection Due to Pseudomonas Aeruginosa.

Insmed

Status and phase: Completed; Phase 2

Conditions: Bronchiectasis

Treatments: Drug: 560 mg Arikayce™; Drug: 280 mg Arikayce™; Drug: Matching Placebo for Cohort 2; Drug: Matching Placebo for Cohort 1

Study type: Interventional

Funder types: Industry

Identifiers

NCT00775138

TR02-107

Details and patient eligibility

About

This is a study to determine the safety and tolerability of 28 days of daily dosing of two doses (280 mg and 560 mg) of Arikayce™ versus placebo in patients who have bronchiectasis and chronic infection due to Pseudomonas infection.

Full description

Bronchiectasis is a chronic disorder of the major bronchi and bronchioles characterized by permanent dilation, microbial infection, a persistent inflammatory response with the release of immune mediators and microbial toxins leading to destruction. The origin of bronchiectasis varies, but the presence of microbial infection and a persistent inflammatory response is typical of the disease. The chronic nature of the infection and the associated considerable morbidity provides the rationale for using aerosolized antibiotics for the treatment of bronchiectasis patients.

This is a multi-national Phase 2 study of safety and tolerability of 28 days of daily dosing with two dose levels (280 mg and 560 mg) of Arikayce™ versus placebo in subjects with bronchiectasis and chronic Pseudomonas infection. Study subjects will be randomized to receive either study drug or placebo by inhalation via a PARI eFlow® nebulizer. Each subject will complete 28 days of daily dosing. All study subjects will be followed for microbiologic activity for 14 days after completion of treatment and for safety for 28 days post completion of study treatment.

The total study duration will be 56 days, with the screening visit occurring within the preceding 14 days prior to study day 1. At Day 1 (baseline), subjects will be evaluated at pre-dose and during the first 4-5 hours post-dose. Subjects will return at Week 2 (day 14) after start of treatment and at the end of Week 4 (Day 28) treatment period to determine safety and efficacy of Arikayce™. Subjects will be followed up on study Days 42 and 56 (about 2 and 4 weeks after end of treatment) for safety determination. After completion of this study, subjects will be followed up for an additional 6 months via phone contacts and records review, if hospitalized or treated for pulmonary exacerbation (under the extension protocol).

Clinical laboratory parameters, audiology testing, clinical adverse events and pulmonary function will be evaluated for all study subjects in order to determine the qualitative and quantitative safety and tolerability of Arikayce™ compared to placebo. Serum, urine and sputum specimens will be collected at periodic intervals to assess pharmacokinetics (PK) in subjects who consent for the PK portion of the study. Additionally, sputum samples will be collected to determine changes in bacterial density. Total Pulmonary Symptom Severity Score (PSSS) will be assessed, and respiratory quality of life will be evaluated by using the St. George's Respiratory Questionnaire (SGRQ). Arikace™,Arikayce™, Liposomal Amikacin for Inhalation (LAI), and Amikacin Liposome Inhalation Suspension (ALIS) may be used interchangeably throughout this study and the other studies evaluating amikacin liposome inhalation suspension.

Enrollment: 64 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Male or female study subjects≥ 18 years of age
• Confirmed diagnosis of multi-focal bronchiectasis in two or more lung segments by HRCT of the chest
• History of chronic infection with P. aeruginosa
• Confirmation of infection with P. aeruginosa at screening
• SaO2 ≥ 90% at Screening while breathing room air
• Ability to comply with study medication use, study visits, and study procedures as judged by the investigator
• Ability to produce at least 0.5 grams sputum or be willing to undergo an induction to produce sputum for clinical evaluation

Key Exclusion Criteria:

• Forced Expiratory Volume in 1 second (FEV1) < 50% of predicted at Screening
• Patients with hemoptysis of ≥60 mL within 4 weeks prior to screening
• Bronchiectasis due to cystic fibrosis (CF), bronchopulmonary Aspergillus, aspiration of foreign body, or secondary to lung compression from tumors
• History of non-tuberculous mycobacterial and/or Aspergillus infection requiring treatment or treated within 2 years prior to screening
• Pulmonary tuberculosis requiring treatment or treated within two years prior to screening
• History of Lung transplantation
• Use of any inhalation or systemic antibiotics (IV antibiotics, or oral antibiotics) within 4 weeks prior to Study Day 1
• Evidence of biliary cirrhosis with portal hypertension
• Smoking tobacco or any substance within 6 months prior to screening, and throughout the study
• History of alcohol, medication, or illicit drug abuse within the 1 year prior to screening

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

64 participants in 4 patient groups, including a placebo group

Cohort 1 - 280 mg Arikayce™

Experimental group

Description:

Subjects in this arm of the cohort 1 will receive 280 mg of Arikayce™

Treatment:

Drug: 280 mg Arikayce™

Cohort 1 - Placebo

Placebo Comparator group

Description:

Subjects in this arm of the cohort 1 will receive matching placebo.

Treatment:

Drug: Matching Placebo for Cohort 1

Cohort 2 - 560 mg Arikayce™

Experimental group

Description:

Subjects in this arm of the cohort 2 will receive 560 mg of Arikayce™

Treatment:

Drug: 560 mg Arikayce™

Cohort 2 - Placebo

Placebo Comparator group

Description:

Subjects in this arm of the cohort 2 will receive matching placebo

Treatment:

Drug: Matching Placebo for Cohort 2